Pharmaceuticals China

China Cancer Immunotherapy Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

China Cancer Immunotherapy Market Industry Trends and Forecast to 2034: Segmented by (Type, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

China · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $9.79 Bn Placeholder estimate
Estimate 2025 $11.03 Bn 8.1% of the global market
Projected 2034 $32.35 Bn 193.3% Adds $21.32 Bn over 9 forecast years
CAGR 2025–2034 12.7% Faster than 64% of 180 Pharmaceuticals markets here
Key players 5
  • China is 8.14% of the global market.
  • In APAC, the largest is China (this report) at $11.03 Bn.
  • Fastest growing: India at 13.7% a year.
  • China ranks 1st of 10 by size in APAC.

Market size projection

China

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$21.32 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Cancer Immunotherapy Market market size by year, China
YearMarket sizeChange that yearSince 2025
2024 (estimate) $9.79 Bn — —
2025 (base) $11.03 Bn +$1.24 Bn —
2026 (forecast) $12.43 Bn +$1.40 Bn +12.7%
2027 (forecast) $14.01 Bn +$1.58 Bn +27%
2028 (forecast) $15.79 Bn +$1.78 Bn +43.1%
2029 (forecast) $17.80 Bn +$2.01 Bn +61.3%
2030 (forecast) $20.05 Bn +$2.26 Bn +81.8%
2031 (forecast) $22.60 Bn +$2.55 Bn +104.9%
2032 (forecast) $25.47 Bn +$2.87 Bn +130.9%
2033 (forecast) $28.71 Bn +$3.23 Bn +160.3%
2034 (forecast) $32.35 Bn +$3.65 Bn +193.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

China Cancer Immunotherapy Market Analysis at a glance
Market size, 2025$11.03 Bn placeholder estimate
Forecast, 2034$32.35 Bn placeholder estimate
Growth (CAGR), 2025–203412.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, indication and end user (see all)
Key playersMerck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Regeneron Pharmaceuticals (see all)
Regulator in ChinaNMPASource: National Medical Products Administration. Checked 14 Nov 2026.
Active clinical trials768 in ChinaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The China Cancer Immunotherapy Market Analysis Executive Summary

Cancer immunotherapy helps the immune system fight cancer, using checkpoint inhibitors, cell therapies, vaccines and other immune drugs.

Key segments of the cancer Immunotherapy market include type (Checkpoint Inhibitors, Cell Therapies and Cancer Vaccines) and indication (Lung Cancer, Melanoma and Blood Cancers).

Bar chart: China Cancer Immunotherapy market size, 2024–2034, placeholder estimates. $9.79 Bn in 2024, $11.03 Bn in 2025 and $32.35 Bn in 2034, 12.7% CAGR.
China Cancer Immunotherapy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

China Cancer Immunotherapy Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the cancer Immunotherapy market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the cancer Immunotherapy market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the cancer Immunotherapy market, especially in low- and middle-income countries.

Competitive Landscape for Cancer Immunotherapy Market in China

The cancer Immunotherapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Cancer Immunotherapy Market in China

Cancer Immunotherapy in China: rules, payment and research

Drugs need approval from the National Medical Products Administration (NMPA) before sale.⁠[1] Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List.⁠[2] ClinicalTrials.gov lists 768 studies on Cancer Immunotherapy that are recruiting, active or about to start in China.⁠[3]

[1] National Medical Products Administration. Checked 14 Nov 2026.

[2] National Healthcare Security Administration. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for cancer Immunotherapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in China.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Cancer Immunotherapy right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Cancer Immunotherapy in context

China compared

  • Health spending per person: 763 US$ per person (2023). World: 1,317 US$ per person (2023). 5th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 3.11 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 14.9% of people (2025). World: 10.4% of people (2025). 6th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Cancer Immunotherapy market in China?
Placeholder estimate: about $11.03 Bn in 2025, rising to about $32.35 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Cancer Immunotherapy market in China growing?
Placeholder estimate: about 12.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Cancer Immunotherapy market report cover?
The report splits the market by type (Checkpoint Inhibitors, Cell Therapies, Cancer Vaccines, Cytokines), indication (Lung Cancer, Melanoma, Blood Cancers, Others) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Cancer Immunotherapy market?
Key players include Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca and Regeneron Pharmaceuticals.
What is driving the Cancer Immunotherapy market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the cancer Immunotherapy market. Faster approvals and new combinations are improving survival.
Who regulates Cancer Immunotherapy in China?
Drugs need approval from the National Medical Products Administration (NMPA) before sale. Source: National Medical Products Administration. Checked 14 Nov 2026.
How is healthcare paid for in China?
Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List. Source: National Healthcare Security Administration. Checked 14 Nov 2026.
How many clinical trials on Cancer Immunotherapy are running in China?
768 studies are recruiting, active or about to start in China, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
How much research is published on Cancer Immunotherapy?
PubMed lists 16,264 papers on Cancer Immunotherapy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in China

See all

Related on oncology

See the topic